BioCentury
ARTICLE | Company News

Bristol-Myers, Ono ink Asia immunotherapy deal

July 24, 2014 11:55 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528) partnered to jointly develop and commercialize multiple products, including Opdivo nivolumab and Yervoy ipilimumab, in Japan, South Korea and Taiwan. The deal also includes early stage BMS oncology compounds lirilumab ( BMS-986015; IPH2102), urelumab ( BMS-663513) and BMS-986016. The partners will jointly pursue development of monotherapy and combination regimens of the immunotherapies.

Under the deal, the partners will share equally development costs and commercial profits when Opdivo is used in combination with any BMS product. BMS will fund the majority of development costs and receive the majority of commercial profits when one of its compounds is used as a monotherapy or two of its compounds are used in combination. Ono will fund the majority of development costs and receive the majority of commercial profits when Opdivo is used as a single agent. ...